LATS1 Antibody Selection Guide: Module Anatomy, Paralog Specificity and Assay Fit
Reading a Kinase Cascade in the Correct Order
LATS1 sits in the middle of a signaling module rather than at its edge. Upstream kinases activate it, and it in turn acts on two transcriptional co-activators. Signal interpretation depends on knowing which step is being measured. An antibody that recognizes total LATS1 reports protein abundance, not kinase activity. Confusing the two is the most common source of contradictory results in this field.
The sections below follow the pathway from input to output. They then turn to the two questions that decide whether a reagent is usable: paralog discrimination and assay matching.
The Module Itself: MST, MOB1 and LATS1
LATS1, large tumor suppressor kinase 1, is a serine/threonine kinase and a core component of the Hippo pathway. That pathway was first described in Drosophila, where it was named for its effect on organ size. It is highly conserved in mammals and controls proliferation and apoptosis, thereby shaping organ size, tissue homeostasis and tumorigenesis.
Activation proceeds through a defined sequence. MST1/2, the STE20-like kinases of the pathway, phosphorylate the hydrophobic motif and the C-terminal domain of LATS1. The modification produces a conformational change and raises kinase activity. The adaptor protein MOB1 then binds LATS1, reinforcing activation and helping to define substrate recognition.
Regulation does not stop there. Phosphorylation, ubiquitination and protein-protein interactions all feed into LATS1 activity. Functional integrity of the kinase is what prevents uncontrolled cell expansion and malignant transformation.
The Two Arms of YAP and TAZ Control
Cytoplasmic Retention Through 14-3-3
Once activated, LATS1 phosphorylates multiple serine and threonine sites on YAP and TAZ. Phosphorylated YAP and TAZ bind 14-3-3 proteins. That interaction holds them in the cytoplasm and blocks nuclear entry. With the co-activators outside the nucleus, TEAD-dependent growth programs cannot be switched on.
Ubiquitin Handover and Degradation
Phosphorylation also recruits E3 ubiquitin ligases. YAP and TAZ are then ubiquitinated and routed to the proteasome. The two arms work together: one removes the co-activator from its site of action, the other removes the protein itself. When LATS1 is lost or downregulated, both restraints disappear. YAP and TAZ accumulate in the nucleus and remain active, driving excessive proliferation. This sequence has been documented in breast, liver and lung cancer models.
Branches Outside the Canonical Axis
Cell Cycle and the Mitotic Apparatus
LATS1 also acts beyond the Hippo module. It influences cell cycle progression by regulating checkpoint proteins and can interact with kinases such as CDK1, contributing to control of the G2/M transition. The kinase localizes to the mitotic spindle and centrosomes, where it participates in checkpoint activation. Loss of that function can produce abnormal chromosome segregation and aneuploidy, a recognized source of genomic instability in tumors.
Phase Separation and a Metabolic Branch
A further layer appears in the figure supplied with this article. GPS2 and LATS1 are shown forming droplets through liquid-liquid phase separation, with the Hippo module marked as upstream input. The same schematic traces YAP into two nuclear routes. One route runs through SREBP1 and the lipogenic enzymes FASN, ACC and ACLY. The other runs through PPAR-alpha and the oxidation enzymes CPT1A and SCAD. Both routes converge on lipid droplet accumulation and on tumorigenesis and progression.
Schematic of the Hippo module feeding YAP into SREBP1-driven lipogenesis and PPAR-alpha-driven fatty acid oxidation, with GPS2-LATS1 phase-separated droplets shown as a regulatory layer
That figure is a model rather than a quantitative result. Its value for reagent selection is conceptual. LATS1 signal may need to be read in more than one compartment, and a nuclear signal and a cytoplasmic signal can carry different meanings.
Reading Phosphorylation Without Overreading It
A phospho-blot for YAP is often treated as a direct measure of LATS1 activity. That inference is reasonable only when total YAP is unchanged. If YAP abundance falls because degradation has already occurred, the phospho-signal can drop even while kinase activity stays high. The same caution applies in reverse: accumulating YAP may dilute the phosphorylated fraction without any change in upstream signaling.
The practical fix is to blot three things together, namely total LATS1, total YAP or TAZ, and the phosphorylated form. Interpreting the triplet is more informative than reading any single band. Where a conclusion depends on kinase activity specifically, an in vitro kinase assay or a downstream transcriptional reporter provides a cleaner endpoint than densitometry on a phospho-blot.
The LATS1 and LATS2 Specificity Problem
The LATS family has two members, LATS1 and LATS2. They share sequence and functional features, which is precisely why subtype specificity determines whether data can be trusted. A pan-LATS reagent will report the sum of both kinases. Any conclusion about LATS1 loss then becomes ambiguous, because compensation by LATS2 can mask the change.
Three practical steps reduce that risk. Confirm the immunogen region against both paralogs before ordering. Run a knockdown or knockout sample alongside wild-type lysate whenever the claim concerns LATS1 specifically. Document the observed band position, because apparent mass differs from the computed value for kinases of this size.
Matching the Reagent to the Question
| Experimental Question | Recommended Readout | What the Result Can Support |
|---|---|---|
| Is LATS1 protein reduced in a tumor set? | Western blot with a loading control | Relative abundance across samples |
| Where is LATS1 distributed in tissue? | Immunohistochemistry on sections | Spatial comparison of normal and tumor tissue |
| Is LATS1 at the spindle or centrosome? | Immunofluorescence | Subcellular localization during mitosis |
| Does LATS1 interact with MOB1 or YAP? | Immunoprecipitation, optionally with phospho-blot | Complex formation and modification state |
Each row answers a different question, and no single assay covers all four. A reagent described as suitable for Western blot, immunohistochemistry and immunoprecipitation gives the flexibility to move between them without changing supplier mid-project.
Product Information
| Product Name | Catalog No. | Host and Format | Target | Applications |
|---|---|---|---|---|
| LATS1 Mouse mAb | S0B60363 | Mouse monoclonal antibody | LATS1 | WB, IHC, IP |
The antibody is supplied in a 25 µl size at ¥600.00. Target validation and lot-to-lot quality control are performed before release. Full buffer composition, concentration and recommended dilutions are listed on the product page and in the batch documents.
Summary
LATS1 is best understood as a convergence point. A change in one kinase alters the localization and stability of both YAP and TAZ. That is why the kinase works as a pathway readout.
Most practical difficulty lies in execution rather than concept. Separate LATS1 from LATS2 before making a loss-of-function claim. Choose the assay that matches the question instead of the assay that is most convenient. Read total protein and activity as different measurements. A reagent that supports Western blot, immunohistochemistry and immunoprecipitation makes that discipline easier to maintain.
ANT BIO PTE. LTD. – Empowering Scientific Breakthroughs
ANT BIO PTE. LTD. supplies high-quality reagents and solutions for life science research. Our sub-brands cover the full research workflow: Starter for antibodies and immunological assay kits, UA-Bio for recombinant proteins and drug discovery solutions, and Absin for general reagents and other detection kits. Explore our product portfolio at www.antbioinc.com.
Disclaimer
This article was partially created with the assistance of artificial intelligence. If any content involves copyright or intellectual property issues, please inform us, and we promise to verify and remove it immediately.
